Generic Sweden (GENI) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 2.4% YoY to SEK 46.4m; gross profit increased 5.0% and EBIT 10.4%, with gross margin 45.9% and EBIT margin 24.2%.

• Jan–Sep revenue increased 7.1% to SEK 144.0m; EBIT rose 5.0% to SEK 30.3m, while operating cash flow declined to SEK 18.2m from SEK 27.1m.

Financial highlights

• Q3 net income was SEK 8.5m versus SEK 8.2m YoY; EPS was SEK 0.69 versus SEK 0.66.

• Jan–Sep net income was SEK 24.2m versus SEK 23.1m; EPS was SEK 1.97 versus SEK 1.88.

• Q3 gross profit was SEK 21.3m, up 5.0%; Jan–Sep gross profit was SEK 64.3m, up 8.0%.

• Q3 EBIT was SEK 11.3m, up 10.4%; Jan–Sep EBIT was SEK 30.3m, up 5.0%.

• Q3 operating cash flow was SEK 7.7m versus SEK 9.7m; Jan–Sep was SEK 18.2m versus SEK 27.1m, mainly reflecting working-capital movements.

Outlook and guidance

• Strategy remains focused on profitable organic growth in Swedish healthcare and e-health, alarms and security, and logistics, with product development, customer expansion, partners, and selective acquisition evaluation.

• Sales capacity is set to strengthen; Magnus Sjölander is scheduled to become Chief Commercial Officer in January 2027, with further sales-team expansion planned.

• Continued demand is expected for secure communications; RCS offers new communication flows and verified-sender functionality alongside SMS.